BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • November 2024
  • September 2024
  • August 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Month: July 2022

3 posts
ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug

Biotech NewsImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug

  • BioTech Health X
  • July 28, 2022
In breaking news, clinical-stage biotechnology company ImmunityBio, Inc. (NASDAQ: IBRX) has announced acceptance by the FDA review of…
0 Shares
0
0
0
0
0
0
0
Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement

Biotech NewsBrickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement

  • BioTech Health X
  • July 20, 2022
Clinical-stage pharmaceutical company Brickell Biotech, Inc. (Nasdaq: BBI) announced that the company has received formal notice from The…
0 Shares
0
0
0
0
0
0
0
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

  • BioTech Health X
  • July 20, 2022
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Aclaris (ACRS) Advances Groundbreaking Therapies for Autoimmune Diseases
  • Pulmonx (LUNG) Reports $68.7M Revenue with 28% Growth and COPD Innovations
  • UroGen (URGN) Posts $25.2M Q3 Revenue, Targets $5B Market with UGN-102 Launch
  • ABBV-RGX-314 Gene Therapy Reduces nAMD Injections in Bilateral Study
  • Rigel (RIGL)’s Q3 2024 Revenue Hits $55.3M
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • November 20, 2024
    Aclaris (ACRS) Advances Groundbreaking Therapies for Autoimmune Diseases
    • November 17, 2024
    Pulmonx (LUNG) Reports $68.7M Revenue with 28% Growth and COPD Innovations
    Genentech Strategic Pivot The Closure of Its Cancer Immunology Unit
    • November 17, 2024
    UroGen (URGN) Posts $25.2M Q3 Revenue, Targets $5B Market with UGN-102 Launch
    • November 14, 2024
    ABBV-RGX-314 Gene Therapy Reduces nAMD Injections in Bilateral Study
    Biogen Expands Immunology Portfolio with Strategic Acquisition
    • November 12, 2024
    Rigel (RIGL)’s Q3 2024 Revenue Hits $55.3M
Recent Posts
  • Lakeside Holding (LSH) Acquires Hupan Pharmaceutical to Enter China’s Medical Logistics Market
    • November 11, 2024
  • Autolus (AUTL) Reports Obe-cel Launch Progress and Strong Cash Position in Q2 2024
    • November 10, 2024
  • Biogen Expands Immunology Portfolio with Strategic Acquisition
    FDA Clears CEL-SCI’s Multikine Study for Head and Neck Cancer
    • November 8, 2024
Categories
  • BioTech CEO Interviews (5)
  • Biotech Info (1)
  • Biotech News (79)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top